ABT

Abbott Laboratories

Add to Watchlist

Advanced Chart

132.660

+1.29(0.982%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

132.845

Open

132.015

VWAP

132.52

Vol

4.43M

Mkt Cap

230.89B

Low

131.170

Amount

587.15M

EV/EBITDA(TTM)

21.74

Total Shares

1.74B

237.31B

EV/OCF(TTM)

26.26

P/S(TTM)

5.38

Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

11.40B

+7.2%

1.299

+7.36%

11.78B

+7.34%

1.490

+11.2%

11.25B

+8.65%

1.221

+12.06%

Estimates Revision

The market is revising Upward the revenue expectations for Abbott Laboratories (ABT) for FY2025, with the revenue forecasts being adjusted by 0.1% over the past three months. During the same period, the stock price has changed by -0.68%.

Revenue Estimates for FY2025

Revise Upward

+0.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.23%

In Past 3 Month

Stock Price

Go Down

-0.68%

In Past 3 Month

20 Analyst Rating

Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 144.83 USD with a low forecast of 135.00 USD and a high forecast of 159.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Buy

3 Hold

0 Sell

Strong Buy

Current: 132.660

Low

135.00

Averages

144.83

High

159.00

Current: 132.660

Low

135.00

Averages

144.83

High

159.00

Jefferies

Matthew Taylor

Hold

Buy

upgrade

$143 -> $145

2025-07-18

Reason

Jefferies

Matthew Taylor

Price Target

$143 -> $145

2025-07-18

upgrade

Hold

Buy

Reason

Jefferies analyst Matthew Taylor upgraded Abbott to Buy from Hold with a price target of $145, up from $143. The firm says that while Abbott's Q2 report and outlook were "underwhelming," the corresponding share selloff is "too punitive." Jefferies recommends taking advantage of the pullback as it believes the company's growth can accelerate in 2026. The stock's current valuation is "compelling for a quality franchise with multiple growth drivers," the analyst tells investors in a research note.

Wells Fargo

Overweight

NULL

downgrade

$147 -> $142

2025-07-18

Reason

Wells Fargo

Price Target

$147 -> $142

2025-07-18

downgrade

Overweight

NULL

Reason

Wells Fargo lowered the firm's price target on Abbott to $142 from $147 and keeps an Overweight rating on the shares after the company reported about in-line Q2 sales and EPS. Abbott lowered 2025 organic sales growth guide due to transitory headwinds in Dx and narrowed its EPS guide. The firm believes the 2026 outlook is intact.

Mizuho

Neutral

downgrade

$140 -> $135

2025-07-18

Reason

Mizuho

Price Target

$140 -> $135

2025-07-18

downgrade

Neutral

Reason

Mizuho lowered the firm's price target on Abbott to $135 from $140 and keeps a Neutral rating on the shares following the Q2 report. The firm cut estimates on the sales guidance revision. The share selloff may be overdone but a potential rebound may be gradual, the analyst tells investors in a research note.

Raymond James

Outperform

maintain

$142 -> $141

2025-07-18

Reason

Raymond James

Price Target

$142 -> $141

2025-07-18

maintain

Outperform

Reason

Raymond James lowered the firm's price target on Abbott to $141 from $142 and keeps an Outperform rating on the shares. Abbott's Q2 results were strong in Med Devices, but idiosyncratic issues are weighing on Diagnostics growth, which is slowing Abbott's momentum, the analyst tells investors in a research note. The firm views these issues as transient.

Mizuho

Neutral

maintain

$130 -> $140

2025-07-16

Reason

Mizuho

Price Target

$130 -> $140

2025-07-16

maintain

Neutral

Reason

Mizuho raised the firm's price target on Abbott to $140 from $130 and keeps a Neutral rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.

Morgan Stanley

Equal Weight

maintain

$127 -> $137

2025-07-15

Reason

Morgan Stanley

Price Target

$127 -> $137

2025-07-15

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Abbott to $137 from $127 and keeps an Equal Weight rating on the shares. The firm continues to like the industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Abbott Laboratories (ABT.N) is 24.53, compared to its 5-year average forward P/E of 24.67. For a more detailed relative valuation and DCF analysis to assess Abbott Laboratories 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

24.67

Current PE

24.53

Overvalued PE

26.88

Undervalued PE

22.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

18.92

Current EV/EBITDA

18.92

Overvalued EV/EBITDA

20.25

Undervalued EV/EBITDA

17.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.85

Current PS

4.97

Overvalued PS

5.27

Undervalued PS

4.42

Financials

Annual

Quarterly

FY2025Q2

YoY :

+7.37%

11.14B

Total Revenue

FY2025Q2

YoY :

+22.38%

2.12B

Operating Profit

FY2025Q2

YoY :

+36.64%

1.78B

Net Income after Tax

FY2025Q2

YoY :

+37.84%

1.02

EPS - Diluted

FY2025Q2

YoY :

+8.27%

1.55B

Free Cash Flow

FY2025Q2

YoY :

+3.52%

53.17

Gross Profit Margin - %

FY2025Q2

YoY :

+27.25%

15.97

Net Margin - %

FY2025Q2

YoY :

+126.27%

25.32

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 121.51% over the last month.

Sold

0-3

Months

746.8K

USD

3-6

Months

337.1K

USD

6-9

Months

78.0M

USD

0-12

Months

18.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

1.9K

Volume

3-6

Months

4.9M

Volume

6-9

Months

190.1K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

379.7K

Volume

Months

6-9

1.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

32.0K

USD

3-6

Months

231.0K

USD

6-9

Months

64.0K

USD

0-12

Months

65.0K

USD

Bought

0-3

16.0K

USD

Months

3-6

16.0K

USD

Months

6-9

72.0K

USD

Months

0-12

91.0K

USD

Months

Insider

Insiders areSelling! The selling amount has increased 121.51% over the last month.

Sold

0-3

Months

746.8K

USD

3-6

Months

337.1K

USD

6-9

Months

78.0M

USD

0-12

Months

18.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ABT News & Events

Events Timeline

2025-08-29 (ET)

2025-08-29

08:01:59

Abbott's Navitor TAVI System Granted CE Mark Approval in Europe

2025-07-17 (ET)

2025-07-17

09:23:18

Abbott sees Q3 EPS $1.28-$1.32, consensus $1.33

2025-07-17

08:29:56

Abbott down 5% at $125.40 after Q2 results, narrowed FY25 outlook

News

4.5

15:00 PMNASDAQ.COM

Investing for the Future: Spotlight on Silver Economy Stocks in the Longevity Era

Global Demographic Shift

Aging Population: The World Health Organization reports that the number of individuals aged 60 and older surpassed those under five in 2020, marking a significant demographic change. By 2050, nearly 22% of the global population will be over 60, with 80% residing in low- and middle-income countries.
Market Growth: The geriatric care services market, valued at approximately $1.21 trillion, is projected to grow to around $2.12 trillion by 2034, reflecting a compound annual growth rate (CAGR) of 6.4%.

Healthcare Sector Transformation

Investment Opportunities: The aging population is reshaping healthcare consumption, leading to long-term investment prospects in pharmaceuticals, medical devices, home care services, and digital health solutions. The launch of the PACE program by CMS exemplifies new community-based healthcare models for seniors.
Pharmaceutical Innovations: Companies like AbbVie, Amgen, Stryker, and Dexcom are adapting to this demographic shift by enhancing operational efficiency and expanding their offerings in the seniors and aging demographics.

Key Players and Innovations

AbbVie: The company is focusing on the aging demographic through strategic acquisitions, such as Aliada Therapeutics for Alzheimer’s treatment, and collaborations in oncology to develop novel immunotherapies. AbbVie is also advancing R&D in immunology and neurodegenerative disorders.
Amgen: Emphasizing biopharmaceutical innovation, Amgen is addressing osteoporosis, which affects over 500 million people globally, and advancing cardiometabolic research with its investigational obesity therapy, MariTide.
Stryker: The orthopedic giant is investing in products for elderly care and has made significant acquisitions, including Inari Medical for vascular solutions and NICO Corporation for neurosurgery technologies, enhancing its capabilities in treating conditions prevalent among older adults.
Dexcom: Known for its continuous glucose monitoring systems, Dexcom is expanding its offerings for seniors, including the G7 CGM system, which has received FDA clearance and is designed for ease of use among older adults.

Investment Resilience

Market Stability: The healthcare sector is viewed as resilient during economic downturns, with consistent demand for critical treatments ensuring stable revenues. This defensive market position offers cash flow stability for investors.
Future Opportunities: Investors are encouraged to explore transformative investment themes, with Zacks highlighting potential high-growth stocks in the healthcare sector, particularly those targeting the aging population.

3.0

09:16 AMYahoo Finance

2025 Remote Patient Monitoring (RPM) Market Analysis: Philips, Medtronic, and Abbott Lead with Cutting-Edge Devices, Worldwide Presence, and Strategic Innovations

Remote Patient Monitoring (RPM) Market Overview

Industry Analysis: The Remote Patient Monitoring (RPM) Companies Quadrant provides a comprehensive evaluation of the global RPM market, highlighting 21 leading companies such as Philips, Medtronic, and Abbott. This analysis emphasizes the role of RPM technologies in reducing healthcare costs and enhancing patient outcomes through home-based care.
Market Dynamics: The report categorizes the RPM market based on components, indications, end users, and regions. It notes that RPM technologies improve healthcare efficiency and reduce hospital workloads, although regulatory challenges across different regions may hinder market growth.

Key Players in the RPM Market

Philips: Koninklijke Philips N.V. stands out as a leader in the RPM sector, leveraging its Connected Care segment to offer advanced patient monitoring systems that enhance clinical workflows and minimize hospital readmissions.
Medtronic: Renowned for its extensive medical device portfolio, Medtronic leads in revenue and invests heavily in RPM innovations, focusing on collaborations and acquisitions to strengthen its market position.
Abbott: Abbott Laboratories excels in chronic disease management through its Diagnostic Products and Medical Devices segments, ensuring a broad market reach and continuous innovation in healthcare solutions.

Trends and Challenges

Technological Advancements: The RPM market is witnessing significant growth driven by digital innovations, the rise of telehealth, and the increasing prevalence of chronic diseases. The demand for cost-effective healthcare solutions is also on the rise.
Regulatory and Behavioral Barriers: High investment costs, lack of IT expertise, and behavioral challenges related to healthcare affordability are identified as major restraints. Additionally, the 2024 CMS regulations present further challenges for market expansion.
Opportunities for Growth: The emergence of AI and machine learning, along with a shift towards outpatient care and hospital-at-home programs, presents new opportunities for RPM technologies.

Competitive Landscape

Evaluation Criteria: The 360 Quadrant evaluates RPM companies based on revenue, geographic presence, growth strategies, and sales strategies. The analysis includes a detailed company evaluation matrix categorizing firms into stars, emerging leaders, and pervasive players.
Investment in Innovation: Key players are actively investing in research and development, forming strategic partnerships, and engaging in collaborative initiatives to drive innovation and maintain a competitive edge in the rapidly evolving RPM market.

Conclusion

Future Outlook: The RPM market is poised for growth, driven by technological advancements and increasing demand for remote healthcare solutions. However, stakeholders must navigate regulatory challenges and invest in innovative technologies to capitalize on emerging opportunities.

9.0

08-29NASDAQ.COM

Abbott Receives CE Mark for Broadened Indication of Navitor TAVI System